Open letter to Ms. Emer Cooke, Executive Director, European Medicines Agency (EMA)
Dear Ms. Cooke, This is an open letter in relation to a question I submitted via EMAs: Send a question to the European Medicines Agency, on 20/12/2020. This is EMAs…
Dear Ms. Cooke, This is an open letter in relation to a question I submitted via EMAs: Send a question to the European Medicines Agency, on 20/12/2020. This is EMAs…
Dear Dr Califf, This is an open letter in follow-up to a question I have submitted to the FDA’s Center for Biologics Evaluation and Research (CBER). The question is repeated…
Bridgend, South Wales, 6th June 2024: Hedley Rees, managing director at PharmaFlow, a 21st century consultancy in biopharmaceutical value chain management, calls for MHRA to investigate if AstraZeneca must instigate…
Who would argue that we innovation in the pharmaceutical industry? Of course you would! Some are even calling for disruptive innovation, to tackle the thorny issues of affordability, availability, and…
Top consultancies report on COVID-19 supply chains The top global consultancies had a lot to say about supply chains during COVID-19. As I was reading over a McKinsey’s assessment recently,…
Bridgend, South Wales, 7th June 2022: PharmaFlow, a 21st century consultancy in biopharmaceutical value-chains, is pleased to announce that founder and managing director, Hedley Rees, has published his latest book…
Bridgend, South Wales, 24th June 2021: PharmaFlow, a 21st century consultancy in biopharmaceutical value-chains, is pleased to announce that Dr Shona Lang will bring Preclinical Evidence Synthesis and Systematic Review…
Bridgend, South Wales, 29th March 2021: Following the chaos and confusion during COVID-19, Hedley Rees has decided to share his deep experience of pharmaceutical production and distribution supply chains, including…
SAMPLE CHAPTER: 10. BACK TO THE FUTURE FOR PHARMA What we now know is that pharmaceutical companies took a wrong fork in the road in the 1980s. Instead of following…
Who would argue that we don't need innovation in biopharmaceuticals? Some are even calling for disruptive innovation, to tackle the thorny issues of affordability and availability of new medical products.…